New data presented at ESCMID Global 2026 in Munich indicate that antiretroviral therapy can substantially slow HIV-associated accelerated biological aging. Researchers reported that, among people living with HIV, ART reduced the gap between biological and chronological age by nearly four years. The update extends earlier findings linking chronic HIV inflammation to premature aging phenotypes. The ESCMID Global presentation also aligns with the broader mechanistic view that persistent immune activation can drive age-associated conditions earlier than in HIV-negative peers. Separately, a companion report described a preprint analysis showing ART improved epigenetic aging measures over roughly 18 months, narrowing differences between biological and chronological age from about 10 years to around 4. Together, the disclosures reinforce ART’s role not only in viral suppression but also in modulating downstream aging-related biology, with potential implications for long-term comorbidity risk management in treated patients.